There is a strong unmet need for new therapeutics to accelerate wound healing across both chronic and acute indications. It is well established that local tissue hypoxia, vascular insufficiency, and/or insufficient angiogenesis contribute to inadequate wound repair in the context of diabetic foot ulcers as well as to other chronic wounds such as venous stasis and pressure ulcers. microRNA-92a-3p (miR-92a) is a potent antiangiogenic miRNA whose inhibition has led to increases in angiogenesis in multiple organ systems, resulting in an improvement in function following myocardial infarction, limb ischemia, vascular injury, and bone fracture. Due to their pro-angiogenic effects, miR-92a inhibitors offer potential therapeutics to accelerate the healing process in cutaneous wounds as well. This study investigated the effect of a development stage locked nucleic acid-modified miR-92a inhibitor, MRG-110, in excisional wounds in db/db mice and in normal pigs. In both acute and chronic wounds, MRG-110 increased granulation tissue formation as assessed by histology, angiogenesis as assessed by immunohistochemistry and tissue perfusion, and wound healing as measured by time to closure and percent closure over time. The effects of MRG-110 were greater than those that were observed with the positive controls rhVEGF-165 and rhPDGF-BB, and MRG-110 was at least additive with rhPDGF-BB when coadministered in db/db mouse wounds. MRG-110 was found to up-regulate expression of the pro-angiogenic miR-92a target gene integrin alpha 5 in vitro in both human vascular endothelial cells and primary human skin fibroblasts and in vivo in mouse skin, demonstrating its on-target effects in vitro and in vivo. Additional safety endpoints were assessed in both the mouse and pig studies with no safety concerns noted. These studies suggest that MRG-110 has the potential to accelerate both chronic and acute wound healing and these data provide support for future clinical trials of MRG-110.
Research over the last decade has unraveled the involvement of the miR-17~92 (OncomiR-1) cluster members (miR-17, miR-18, miR-19a, miR-19b-1, miR-20a, and miR-92a-1) in a large variety of physiological and pathophysiological processes.
1 miR-92a −/− mice are generally viable but show skeletal abnormalities in the forelimbs. 2 To the best of the authors' knowledge, wound healing has not yet been assessed in miR-17~92 or miR-92a knockout mice. Although cluster members miR-18a and miR-19a were shown to have pro-angiogenic functions, 3 miR-92a-3p has been shown to play an inhibitory role in angiogenesis. [4] [5] [6] [7] [8] miR-92a-3p is highly expressed in endothelial cells as compared to other members of the miR-17~92 cluster. 4 Overexpression of miR-92a in human endothelial cells repressed expression of pro-angiogenic factors such as integrin alpha-5 (ITGA5), slowed migration of endothelial cells, affected the ability of endothelial cells to adhere to fibronectin, blocked vascular networking in the Matrigel assay, and inhibited sprout formation in vitro. 4, 9 Forced overexpression of miR-92a in vivo was found to block vessel formation in zebrafish, and resulted in fewer perfused lectin-positive vessels in a Matrigel plug assay in nude mice. 4 Conversely, miR-92a inhibitors have been shown to have pro-angiogenic effects in vivo in various animal models, including in acute myocardial infarction models in mouse and pig, 4, 5 in hind limb ischemia models in mouse, 4 and improved vessel repair following neointimal injury in mouse and rat. 6, 7 In the cutaneous context, a light-inducible antimiR-92a functioned to increase angiogenesis, granulation tissue formation, and wound healing in excisional wounds in db/db mice, 8 a wellaccepted model of diabetic impaired wound healing. [10] [11] [12] [13] [14] Collectively, these data show that miR-92a is involved in the regulation of angiogenesis in multiple species and tissues. This suggests that a potent antagonist to miR-92a may function as an effective therapeutic to increase angiogenesis/ revascularization in the heart and skin, and in the context of ischemic cutaneous wounds such as diabetic foot ulcers, to improve healing.
In this study, we performed a screen of multiple locked nucleic acid (LNA)-modified miR-92a inhibitors and selected one (MRG-110) for preclinical development based on activity in vitro and in vivo. MRG-110 increased expression of multiple miR-92 pharmacodynamic targets in both human vascular endothelial cells (HUVEC) and primary human skin fibroblasts in vitro. In excisional wounds in the db/db mouse, intradermally administered MRG-110 increased wound reepithelialization, granulation tissue formation and angiogenesis, and increased ITGA5 protein expression without inducing systemic toxicity or distal angiogenesis. In a wound healing study performed in normal pigs, MRG-110 also increased acute excisional wound healing, granulation tissue formation and angiogenesis without inducing systemic toxicity. Finally, combination studies with MRG-110 and platelet derived growth factor (rhPDGF-BB) indicated that the two therapeutics may have a combinatorial effect, suggesting that MRG-110 may be beneficial in improving the revascularization and healing of both acute and chronic cutaneous wounds in the presence and absence of other treatments (e.g., becaplermin).
METHODS

Oligonucleotide synthesis
In vitro and in vivo mouse studies used oligonucleotides that were produced via solid phase support synthesis at miRagen Therapeutics, Inc. (Boulder, CO) and formulated in phosphate buffered saline (PBS). MRG-110 is a developmentstage oligonucleotide inhibitor of miR-92a-3p. AntimiR-92a #2 and #3 are additional oligonucleotide inhibitors with the same nucleotide sequence and target but unique LNA-DNA modification patterns. CTRL antimiR is an LNA-DNA based oligonucleotide with the same length and similar structure, which does not target miR-92a. A double-stranded miR-92a mimic was used for select in vitro studies. All oligonucleotides were sterile filtered following formulation. Vehicle control was sterile PBS. MRG-110 manufactured at Biospring GmbH (Frankfurt, Germany) was used for the good laboratory practice (GLP) pig local tolerability study completed at MPI research (Mattawan, MI). All oligo doses are expressed based on the active moiety (free acid).
Mouse in vivo studies
All animal studies were completed under a protocol approved by the appropriate IACUC and in accordance with the policies outlined in the National Institutes of Health "Guide for the Care and Use of Laboratory Animals". Mouse studies were performed at miRagen Therapeutics, Inc. (Boulder, CO). Male db/db mice (6-8 weeks old, n = 8-10 as indicated in each figure legend) were anesthetized with 2-5% inhaled isoflurane and were maintained under 1% isoflurane for all procedures. Buprenorphine (0.1 mg/kg) was used as an analgesic for all surgical procedures. Animals were anesthetized, depilated by shaving and administration of Nair hair removal cream, and the skin site was prepared for excision by betadine and alcohol surgical scrub. Two 6-mm diameter full-thickness excisional skin wounds were created on the dorsal skin and were covered with Tegaderm transparent semi-occlusive dressing (3M, Maplewood, MN) as described previously. 10 At the time of surgery, and on postsurgical days 2, 4, and 8, animals were treated with intradermal injections of 1-100 nmol of miR92a inhibitor, vascular endothelial growth factor (rhVEGF-165) (1 μg/wound, Peprotech, Rocky Hill, NJ), rhPDGF-BB (2 μg/wound, Peprotech) or vehicle (PBS). Each treatment was distributed around the outside of the skin wound as four 25 μL intradermal injections placed such that the injection bleb touched the edge of the wound. On postoperative day 10, mice were euthanized by overdose of isoflurane anesthetic, followed by cervical dislocation. Tissue at the treatment site(s) was harvested with a 10 mm biopsy punch, removing the skin down to the underlying fascia. Skin samples were bisected and half of the wound was formalin fixed and paraffin embedded for histology and immunohistochemistry analysis. The other half of the skin sample, as well as samples from the largest lobe of the liver, the center of the kidney including cortex and medulla, the spleen, a distal skin piece, and/or plasma was snap-frozen in liquid nitrogen for analysis of tissue biodistribution. Plasma samples were evaluated for the liver/kidney dysfunction using clinical chemistry assessments (alanine transaminase, aspartate transaminase, blood urea nitrogen, and creatinine assays) (colorimetric assays provided by Bioo Scientific, Austin, TX).
Histology
Histology processing of all mouse skin samples was performed at HistoTox Labs (Boulder, CO). Hematoxylin and eosin staining were performed for each tissue sample, as well as immunohistochemistry for CD31 and for ITGA5. Hemotoxylin & eosin stained wounds were assessed for ingrowth of granulation tissue and reepithelialization. Full slide scans of all slides were captured at HistoTox Labs at 20× magnification using an Aperio AT2 scanner, blinded, and analyzed using Aperio ImageScope or using ImageJ. In all cases, the wound edges were identified as either the transition point from normal skin dermis to granulation tissue or as the last remaining hair follicle in the unwounded skin, whichever was closer to the center of the wound. The wound width, granulation tissue gap, and granulation tissue area were measured. Voids in the tissue or large fat globules were excluded from the analysis. Length and area measurements were calculated based on a global scale in ImageJ (National Institutes of Health, Bethesda, MD) or using the integral image scale in Aperio. Measurement values were transferred into Excel (Microsoft, Redmond, WA), and the % reepithelialization was calculated using the formula [1 −epithelial gap/wound width]*100, % granulation tissue filled was calculated using the formula [1−granulation tissue gap/wound width]*100, and granulation tissue thickness was calculated using the formula [granulation tissue area/wound width]. CD31 immunostaining was performed using a chromogenic secondary antibody and substrate. Slides were lightly counterstained with hematoxylin to indicate the location of cell nuclei/general tissue morphology. The stained slides were blinded and the left and right wound edges were photographed at 10× magnification under bright field, or full slide scans were captured as described earlier. Blood vessel/ endothelial cell number and size, as well as total tissue area were quantitated using user-generated macros in ImageJ. ITGA5 protein expression in blood vessels at the edge of healing wounds was assessed using immunostaining with a chromogenic secondary antibody and substrate, and hematoxylin counterstain. Full slide scans of all slides were captured at HistoTox Labs at 20× magnification using an Aperio AT2 scanner. Images were blinded and opened using Aperio ImageScope. A region of interest (ROI) at the left and right wound edges was circled using the pen tool by one blinded reviewer. Two additional blinded observers then scored the staining intensity of the blood vessels within the ROI from 0 (no staining) to 4 (maximal staining). Data were inserted into Excel and the mean of the two observers was used for statistical analysis.
Tissue biodistribution
A sandwich hybridization assay was used for the quantification of antimiR-92a oligonucleotide in plasma and tissue samples. The capture and detection probes for the hybridization assay were synthesized at miRagen using all LNA modified nucleotides. Samples were homogenized in guanidine isothiocyanate buffer and applied to a streptavidin plate (Streptawell HighBind Streptavidin Plates, Roche, Basel, Switzerland) coated with a biotin labeled capture probe. Bound antimiR-92a was then bound with a fluoresceinlabeled detection probe. Following washes to remove any unbound material, the fluorescein-labeled oligonucleotide sandwich was detected by sequential incubation with an anti-fluorescein Fab fragment conjugated to horseradish peroxidase (HRP) (Roche, Basel, Switzerland) followed by the TMB colorimetric HRP substrate (KPL). Standard curves were generated using dilutions of each specific antimiR and were fit by nonlinear logistic regression analysis with four parameters.
Pig in vivo studies
All studies using pigs were performed as part of a GLP local tolerability and wound healing study at MPI Research (Mattawan, MI). Briefly, female domestic Yorkshire crossbred pigs (farm pigs) weighing approximately 50 kg were used (n = 8 pigs). Animals were anesthetized and prepared for surgery as per MPI Research standard operating procedure (SOP). Each animal received eight 2.5 × 2.5 cm fullthickness excisional wounds on the back. The wounds were separated from each other to avoid wound-to-wound interference (5-10 cm). The treated animals (n = 6 pigs) were administered MRG-110 at low (2.8 mg, 0.45 mg/cm 2 ), mid (11 mg, 1.8 mg/cm 2 ), and high (45 mg, 7.2 mg/cm 2 ) doses at each of two wounds on each dosing day, and received vehicle control (VC, 105 mM phosphate buffer prepared in water for injection) or standard of care (SOC, consisting of wound dressing only) at one wound each. MRG-110 and vehicle were dosed as twelve 100 μL intradermal injections distributed evenly around the edge of each wound (three injections per side). A control group of two animals underwent the same surgical procedure and received intradermal injections of VC or SOC at each of four wounds, with no exposure to MRG-110. The test article or vehicle was administered to all groups via intradermal injection, once a day, three times a week for 2 weeks (days 0, 2, 4, 7, 9, and 11). Each dose level was randomized among the wounds for treatment. During the study, all wounds were dressed with nonadherent absorbable dressings, held in place using a sheet of Bioclusive or equivalent transparent dressing. The pig was then wrapped with VetWrap or the equivalent and jacket or surgifix stocking used to keep bandages in place. Wounds were photographed on days 0, 4, 7, 11, 14, 17, 21, 24, 28, 31, 35, 38, 43 46, and 49 for morphometric assessment of wound closure (ImageJ 1.32j software). Laser Doppler assessment of blood flow in the peri-wound area was performed on day 0, 7, 14, 21, 28, 35, 43, and 49. Animals were euthanized on day 49, by euthanasia solution administration, under sedation (acepromazine and/or Telazol), followed by an MPI Research SOP approved method to ensure death (e.g., exsanguination). Skin wound samples were formalin fixed and paraffin embedded and histopathological analysis of epithelial thickness, granulation tissue formation, and vascularization was performed by Alizée Pathology, LLC (Thurmont, MD). Vascularization was assessed on a four point scale (0, none; 1, minimal; 2, moderate; 3, marked), epithelial thickness was assessed on a three point scale (1, thinner than normal skin; 2, comparable to normal skin; 3 thicker than normal skin), and granulation tissue formation within the normal boundaries of the dermis and subcutaneous space was assessed on a five point scale (0, no; 1, minimal; 2, mild; 3, moderate; 4, marked granulation tissue). Drug biodistribution in pig skin samples was assessed using a qualified highperformance liquid chromatography with fluorescence detection (HPLC-FD) assay performed at Covance (Salt Lake City, UT).
In vitro studies
HUVEC PD (pooled donor, Cell Applications, San Diego CA, 200p-05n) and HUVEC PS (pre-screened for VEGF expression, Cell Applications, San Diego, CA, S200-05n) endothelial cells were grown in cell applications endothelial basal medium + growth supplement. HS895-SK (ATCC CRL-7636), CCD-986SK (ATCC, CRL-1947), and CCD-1059SK (ATCC, CRL-2072) primary human fibroblasts were grown in Dulbecco's modified Eagle's medium with the addition of L-glutamine, sodium pyruvate, antibiotics/ antimycotics, and FBS. Cells were seeded in 12-well plates and actively transfected with MRG-110 using Dharmafect reagents (Dharmacon, Lafayette, CO), or subjected to mock transfection (Dharmafect lipid alone). Total RNA was isolated 48 hours later using Trizol (Thermo Fisher Scientific, Waltham, MA) or Qiagen RNeasy 96 kits (Qiagen, Hilden, Germany), as per the manufacturer's standard protocols.
Microarray analysis
Affymetrix hu133 plus 2.0 arrays (Santa Clara, CA) were used for gene expression analysis. Analysis was performed using ArrayStudio (version 9.0.2.46) and hierarchical clustering was performed in Array Studio using an agglomerative metric with Euclidean distance. Three individual replicates for each treatment were profiled. One sample for miR-92a treatment failed QC and was therefore eliminated from the analysis. Genes were selected on the basis of differential expression (FDR p-value ≤ 0.05) for miR-92a treatment vs. untreated cells. The gene expression fold-changes are plotted on a red to blue colorimetric scale, where red represents genes with increased expression and blue represents genes with reduced expression following oligonucleotide treatment compared to vehicle treatment.
Quantitative real-time PCR analysis
Cellular miR-92a expression was quantified using Taqman PCR (Life Technologies, Carlsbad, CA) quantified relative to a standard curve of miR-92a synthetic RNA (Dharmacon, Lafayette, CO). For real-time PCR analysis of miR-92a target gene expression, up to 1 μg RNA from each cell culture sample was used to generate cDNA using Applied Biosystems (Foster City, CA) high capacity cDNA reverse transcription kit per manufacturer's specifications (Thermo Fisher Scientific). The expression of a subset of genes was analyzed by quantitative real-time PCR using Taqman probes purchased from Life Technologies. Reagents are listed in Supporting Information Table S1 .
Statistical analysis
Statistical analysis was performed in Prism (v7.03, GraphPad, La Jolla, CA). All graphs are presented as mean AE standard error of the mean. Graphs with an n < 6 are presented as mean AE standard deviation and are indicated as such in the figure legend. For normally distributed data, one-way analysis of variance (ANOVA) was used to determine significance. Data that were not normally distributed were analyzed using Kruskal-Wallis test. Post hoc assessments were performed relative to PBS controls in all cases. Primary and post hoc statistical tests are indicated for each figure. A pvalue of ≤0.05 was considered statistically significant.
RESULTS
To investigate the effects of miR-92a antagonism on cutaneous angiogenesis and wound healing, excisional wounds created on db/db mice were treated with intradermal injections of various oligonucleotide inhibitors to miR-92a (10 to 100 nmol/dose/ wound). Positive controls included rhVEGF-165 (1 μg/wound, dose equivalent to reference 15) and rhPDGF-BB (2 μg/wound, dose equivalent to the human dose of becaplermin gel (Regranex, Smith and Nephew, London, UK), dosed based on wound surface area). Vehicle injected wounds served as negative controls. Occlusion with a Tegaderm dressing (3M, Maplewood, Minnesota) was used to prevent desiccation and to prevent the wounds from closing due to contraction, as previously described. 12 A total of nine studies were performed, and one lead compound (MRG-110) was identified based on histologic assessment of efficacy in vivo. In all 9/9 studies, MRG-110 increased granulation tissue formation relative to vehicle control to a level equal to or greater than rhVEGF-165 or rhPDGF-BB, and in 7/9 studies, MRG-110 increased wound reepithelialization. Representative data are presented in Figure 1 and Supporting Information Figure S1 . The response to MRG-110 was dose-dependent, with maximal effects seen at or near 100 nmol/dose/wound (~2 mg/cm 2 ) ( Figure 1F,G) . Notably, at this dose, MRG-110 doubled the area (Figure 1F , 1.9X) and thickness ( Figure 1G, 2.2X ) of granulation tissue as compared to vehicle treated wounds. Other oligonucleotide inhibitors to miR-92a were either similarly efficacious (antimiR-92a #3, Supporting Information Figure S1 ), less potent (antimiR-92a #2, Figure 1 and Supporting Information Figure S1 ), or were not active in vivo (data not shown). An irrelevant control oligonucleotide with similar chemical structure, but which does not target miR-92a, had no effect on wound healing (Supporting Information Figure S1 ). Angiogenesis was assessed by quantification of CD31+ endothelial cells and blood vessels via immunohistochemistry. rhPDGF-BB exerted a minimal effect on angiogenesis, whereas MRG-110 significantly increased the number (2.1× vs. vehicle control) and size of blood vessels (1.3×) at the wound edge as well as the total tissue area stained with CD31 (2.7×) as compared to vehicle treated wounds (Figure 2 , arrows indicate wound edge).
The effect of MRG-110 on miR-92a target gene expression was assessed in vitro and in vivo. Microarray analysis was performed on HUVEC cells actively transfected with either a double-stranded miR-92a mimic (1 nM) or MRG-110 (10 nM). A set of 29 genes significantly regulated by miR-92 mimic was identified (Benjamini Hochberg FDR p < 0.05). This signature of genes was perfectly reciprocally regulated by the miR-92a inhibitor, MRG-110 ( Figure 3A) . Included in this signature is the well-described miR-92a target ITGA5. In a separate in vitro study, ITGA5 was confirmed to be de-repressed (up-regulated) in HUVECs by active transfection of MRG-110 ( Figure 3B ). Other direct targets (CNEP1R1, ERGIC2, MAN2A1 are all 8-mer seed matches, CD93 is a 7-mer seed match) and indirect targets (e.g., SERPIND1, STAT3) of miR-92a were similarly upregulated (Supporting Information Figure S2B ). Furthermore, ITGA5 was de-repressed in vivo. ITGA5 immunostaining of db/db skin wounds showed significant increase in the staining intensity of blood vessels at the edge of MRG-110-treated wounds but not PDGF-treated wounds ( Figure 3C-F, arrows) . In addition, there was also an observable increase in ITGA5 protein expression in fibroblasts and other cells in the wound bed following MRG-110 treatment ( Figure 3F, arrowheads) . Therefore, it was hypothesized that MRG-110 also exerts an effect on miR-92 target gene expression in fibroblasts. Although endogenous miR92a expression was 4-fold lower in primary skin fibroblasts than in HUVECs (Supporting Information Figure S2A ), MRG-110 also de-repressed expression of ITGA5 and other direct and indirect miR-92a target genes in fibroblasts, albeit at a lower dose and smaller effect size (fold-change) than in HUVECs (Supporting Information Figure S2B,C) .
Systemic uptake and distribution of phosphorothioate oligonucleotides is known to be broad. 16 Distribution of intradermally administered MRG-110 was consistent with other similar molecules ( Figure 4A) , with substantial MRG-110 uptake into the liver, kidney, and spleen. However, no signs of systemic toxicity (e.g., elevations in ALT, AST, BUN, or Creatinine levels in plasma) were observed in the mouse, even when MRG-110 was administered at very high doses (40 mg/kg, Figure 4B -F). Additionally, in the mouse, the effects of MRG-110 in the skin appeared to be highly localized; transfer of MRG-110 to distal skin was minimal; drug accumulation in distal skin was 6-to 10-fold lower than in treated wounds ( Figure 4A ) and drug accumulation in contralateral control wounds on distally treated mice was similarly low (data not shown). In addition, no significant improvement in granulation tissue formation or angiogenesis was observed in contralateral wounds of mice treated with MRG-110 ( Figure 4G-J) . Next, MRG-110 was tested in combination with rhPDGF-BB, the active pharmaceutical ingredient in becaplermin gel, the only drug to be FDA-approved for treatment of diabetic foot ulcers (Regranex). As seen in our previous studies, PDGF treatment increased wound reepithelialization, and modestly, but statistically significantly increased granulation tissue formation ( Figure 5 ). As seen in our previous studies, but in contrast with some reports in the literature, 11,17 PDGF treatment had a very minimal effect on wound angiogenesis ( Figure 5 ). In this study, MRG-110 was administered at the optimal dose (0.5 mg, 92 nmol), and at a subefficacious dose (0.16 mg, 30 nmol). As seen previously (Figure 1 and Supporting Information Figure S1 ), MRG-110 resulted in a dosedependent increase in wound reepithelialization, granulation tissue formation, and angiogenesis ( Figure 5 ). The combination of PDGF with the sub-optimal dose of MRG-110 resulted in a level of reepithelialization comparable to PDGF alone (1.8× vehicle controls), angiogenesis comparable to the low dose of MRG-110 alone (100% granulation tissue filled vs. 58% in vehicle group), and granulation tissue formation greater than any other treatment group (granulation tissue area 3× vehicle controls, granulation tissue thickness 3.9× vehicle controls; Figure 5 ), suggesting that there is an additive or synergistic effect between the two therapeutics.
Finally, the effects of MRG-110 on acute wound healing were investigated in a GLP local tolerability and wound healing study in normal pigs. Dose levels were selected based on the optimal effective dose in mouse (~2 mg/cm 2 ) as well as four-fold lower and higher doses. MRG-110 was well tolerated in all animals; no local tolerability or systemic toxicology findings were attributed to the test article. Angiogenesis was assessed by both laser Doppler imaging for cutaneous perfusion and by histology for vascularization. On day 14, 3 days after the last dose, the mean laser Doppler perfusion values were increased for all animals treated with MRG-110 as compared to animals treated with SOC and VC only. Statistically significant increases in blood flow perfusion units were noted in the wounds treated with all dose levels of MRG-110 as compared to the vehicle control wounds on untreated pigs on day 14 (1.9-2×, p < 0.05) indicating an increase in perfusion and/or revascularization ( Figure 6A ). Histologic assessment of vascularization from tissue samples taken on day 49, 5 weeks after the last MRG-110 dose, showed a persistent and significant increase in vascularization following low and high dose MRG-110 treatment ( Figure 6B ).
Acute wound repair was assessed by wound photography to measure wound size and rate of healing ( Figure 4F-H) and by histopathology on day 49 ( Figure 4C-E) . MRG-110 accelerated acute wound repair; beginning on day 14 until study termination, marked improvements in healing were noted in all MRG-110 treated sites compared to untreated . These experiments demonstrate that MRG-110 increased the expression of ITGA5 in blood vessels (arrows) and fibroblasts (arrowheads) at the wound margin of treated wounds and that up-regulation of ITGA5 is statistically significant in cells and tissues treated with MRG-110. n = 6 biological replicates for in vitro experiments, n = 5 mice, 2 wounds per mouse. * = p < 0.05, **** = p < 0.0001, one-way ANOVA with Dunnett's multiple comparisons.
control animals ( Figure 4F-G) and the time to 50% wound closure was reduced by 1 week relative to vehicle control ( Figure 4H ). On day 35 of the study, complete wound closure was achieved in 7 of 12 wounds (58%) treated with the lowest dose of MRG-110 compared to 0 of 8 (0%) SOC and 1 of 8 (12%) VC treated wounds on drug naïve animals Figure 4 . Systemic effects of MRG-110 treatment in db/db mice. (A) Tissue distribution of MRG-110 was assessed via sandwich hybridization assay, 48 hours after the last of four intradermal treatments of MRG-110 around an excisional wound in db/db mice (n = 8 mice). Accumulation was observed in skin at the dosing site, liver, kidney, and spleen. Analysis of (B) alanine transaminase, (C) aspartate aminotransferase, (D) blood urea nitrogen, and (E) creatinine (n = 10 db/db mice) indicated that neither rhPDGF-BB nor MRG-110 resulted in an increase in the liver or kidney disfunction relative to control db/db mice, but that all db/db mice exhibit poor liver function compared to normoglycemic C57BL/6 mice (n = 4 C57BL/6 mice, glucose determination in panel F). Quantification of (G) reepithelialization, (H) granulation tissue ingrowth, (I) granulation tissue area, and (J) granulation tissue thickness in vehicle-treated contralateral control wounds in db/db mice treated with MRG-110 at a distal wound site demonstrated that there was no significant improvement in wound healing of contralateral wounds as compared to vehicle-treated wounds on untreated mice (n = 10 mice per group). † = p < 0.05, † † = p < 0.01, † † † = p < 0.001, Kruskal-Wallis test. **** = p < 0.0001, one-way ANOVA with Dunnett's multiple comparisons.
( Figure 4G ). Histologic assessment on day 49 demonstrated a statistically significant increase in granulation tissue formation in the pig ( Figure 4D ,E), consistent with improved wound healing overall in MRG-110 treated wounds. MRG-110 retention in the skin was also assessed on day 49 by HPLC-FD assay (Table 1) . Skin tissue concentrations of MRG-110 at wound sites were variable but demonstrated prolonged high MRG-110 exposure with all three dose levels that were tested. In addition, wounded skin that received VC or SOC treatment had moderate amounts of test article, whereas unwounded skin in the same animals showed much less MRG-110 accumulation (4.4-fold lower than VC or SOC wounds). Interestingly, unlike our previous observations in the mouse, MRG-110 also impacted the healing of distal control wounds on animals receiving treatment at other wound sites. Slight improvements in angiogenesis (perfusion and vascularization) and wound healing (granulation tissue formation and closure rates) were observed in untreated (SOC) or vehicle-treated (VC) wounds secondarily exposed to systemic MRG-110 originating from distal treated sites as compared to untreated (SOC) or vehicle-treated (VC) wounds on animals that did not receive MRG-110 treatment (Supporting Information Figure S3 ).
DISCUSSION
There is a strong need to improve the healing of chronic wounds such as diabetic foot ulcers, venous stasis ulcers and pressure ulcers, as well as to improve acute wound healing in vulnerable patient populations (e.g., aged, obese, diabetic). However, depending on the indication and on the region of the world a patient resides in, there are few, if any, approved therapeutics currently available to accelerate skin wound healing. Becaplermin gel (Regranex) is currently the sole pharmaceutical drug approved for treatment of diabetic foot ulcers in the USA, although the label carries a "black box warning" for increased risk of mortality secondary to malignancy, 18 and its marketing authorization for the European Union was voluntarily withdrawn in 2012.
19 Furthermore, the efficacy of becaplermin gel has not been established for the treatment of less severe diabetic neuropathic ulcers (Stage I or II, IAET staging classification), ischemic diabetic ulcers, pressure ulcers, or venous stasis leg ulcers (Regranex prescribing information and Weiman 20 ), indicating that the clinical use of this therapeutic is limited to only a subset of nonhealing wounds (reviewed in Fang and Galiano 21 ). Therefore, there is a strong unmet need for additional therapeutics to accelerate wound healing across both chronic and acute indications. Other growth factor-based therapeutics have shown promise preclinically but have yet to be confirmed as safe and effective clinically. Although rhVEGF-165 has been shown to increase healing in db/db mouse models 10, 15 and early clinical trials of rhVEGF-165 (Telbermin, Genentech, South San Francisco, CA) showed promise, 22 clinical trials for VEGF have been halted after a phase 2 study generated negative results (Genentech public disclosure January 14, 2008 23 ). Other recombinant growth factors have either failed preclinically or clinically, likely due to the high protease content of chronic wound fluid or due to the failure of a single peptide therapeutic to replace the numerous growth factors that are dysregulated in chronic wounds. 24, 25 Due to this, many researchers and companies have investigated the use of advanced growth factor delivery systems, 26 cell based delivery systems, 27 platelet rich plasma, 28 advanced therapeutic dressings 29 or others, to overcome the limitations of a single recombinant growth factor therapy. However, none of those therapies has been fully integrated into the standard of care, due to a lack of strong evidence showing a clinical benefit, and due to a lack of understanding of the mode of action of these "medical devices."
Another approach to improve the healing of chronic wounds and acute wounds alike is to correct the underlying problems contributing to slow healing, thereby restoring tissue homeostasis. MicroRNAs have been shown to be critical regulators of gene pathways and have been implicated in the pathology of diseases such as obesity, 30 diabetes, 31,32 cardiovascular disease, 33 aging and other agerelated diseases. 34 Therefore, therapeutics that modulate a miRNA's expression or function have the potential to be disease modifying. It is well-established that local tissue hypoxia, vascular insufficiency, and/or aberrant angiogenesis contribute to inadequate wound repair in the context of diabetic foot ulcers 21, 35, 36 as well as to other chronic wounds such as venous stasis and pressure ulcers. 37 Increases in local angiogenesis can therefore be anticipated to contribute to better wound healing for chronic wounds 21, [35] [36] [37] as well as increased survival of grafts and flaps 38, 39 and potentially may improve acute wound healing across a broad range of acute injury events. 39 As indicated earlier, miR-92a-3p is an antiangiogenic microRNA and inhibition of miR-92a has pro-angiogenic effects in the cardiovascular system and skin alike. [4] [5] [6] [7] [8] This study demonstrates that a novel LNA-modified antimiR-92a, MRG-110, accelerates angiogenesis, increases granulation tissue formation, and accelerates wound closure in compromised and acute wounds in both mice and pigs. These results suggest that MRG-110 may be an effective therapeutic for treatment of chronic and acute wounds alike. In addition, the effects of MRG-110 were at least additive with rhPDGF-BB, indicating that MRG-110 may be used alone or in combination with becaplermin.
In both HUVEC cells and human skin fibroblasts, the pharmacodynamic effects of MRG-110 transfection were not dose-responsive but rather, demonstrated a threshold effect with active doses falling within at least a 100-fold dose range and with lower doses having little effect (data not shown). In contrast, in the db/db mouse, the pharmacodynamic effect of MRG-110 was dose-responsive, with 2 mg/cm 2 being the most efficacious dose and with a 3-to 10-fold decrease in drug administration resulting in a smaller effect on granulation tissue formation and angiogenesis. In the pig, MRG-110 was similarly efficacious at all doses tested (0.45-7.3 mg/cm 2 ). The combination of in vitro and pig data indicates that MRG-110 is active over broad dose ranges and suggests that the decreased response in the mouse at low doses may be due to the rodent's unique skin physiology. Because pig skin is physiologically more similar to human skin, this suggests that MRG-110 may potentially be effective at low clinical doses. This also suggests that local treatment of a wound could be used to expose a patient to very low systemic doses, thereby decreasing the likelihood of systemic adverse reactions. It is also notable that in these experiments, there was very little effect observed in contralateral control wounds in MRG-110 treated mice, whereas there was a demonstrable, albeit not statistically significant, treatment effect in distal "standard of care" (dressing only) and "vehicle" (dressings plus saline injection) treated wounds on MRG-110 treated pigs. This difference may be due to the relative exposure of the untreated skin wound to drug; in the mouse there was a >6-fold decrease in drug accumulation in distal skin and contralateral treatment sites as compared to dosed wounds ( Figure 4A and data not shown), whereas in the pig there was a <4-fold difference in drug exposure from VC or SOC treated wounds as compared to the low dose . Both PDGF and MRG-110 increased reepithelialization and granulation tissue formation, and the combination treatment had a greater effect on granulation tissue formation than either treatment alone. Analysis of (E) CD31+ endothelial cell and blood vessel counts, (F) CD31+ particle size, and (G) CD31+ area (n = 10 mice, two wounds per mouse). MRG-110 treatment significantly increased wound angiogenesis in a dose-dependent fashion, independent of PFGF treatment. † = p < 0.05, † † = p < 0.01, Kruskal-Wallis test.
treated wounds (Table 1) . This difference may help inform the minimum anticipated biological effect level for MRG-110 in the skin. This difference may also be the result of differing skin physiology/morphology between the two species, with the pig expected to be more representative of the human situation. In addition to local administration, this indicates that there may be the opportunity for low dose systemic administration of MRG-110 to treat large or multiple wounds on the same individual. The safety, tolerability, and pharmacodynamic response to MRG-110 is currently being tested in two phase 1 clinical trials, the first using systemic administration and the second using local administration at the site of an acute excisional wound (Clinicaltrials.gov reference numbers NCT03494712 and NCT03603431, respectively). 
